PCM
TBPH icon

Portolan Capital Management’s Theravance Biopharma TBPH Stock Holding History

Portolan Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-18,084
Closed -$577K – 121
2014
Q2 		$577K Buy
+18,084
New +$544K 0.13% 109

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
FAM
Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Portolan Capital Management's TBPH Position: Q3 2014 in Review

Portolan Capital Management sold out of Theravance Biopharma (TBPH) in Q3 2014, closing a stake of 18,084 shares — an estimated $577K sold.

Portolan Capital Management first reported a position in TBPH in Q2 2014 and held it in 1 quarter. The position peaked at $577K in Q2 2014. 91 funds tracked by Wall St. Rank hold TBPH as of Q3 2014.

  • Portolan Capital Management reported no remaining Theravance Biopharma position as of Q3 2014 after selling out during the quarter.
  • Portolan Capital Management sold 18,084 Theravance Biopharma shares in Q3 2014, an estimated $577K.
  • Portolan Capital Management first reported a position in Theravance Biopharma in Q2 2014 and held it in 1 quarter.
  • Portolan Capital Management's Theravance Biopharma position peaked at $577K in Q2 2014.
  • 91 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2014.

Based on Portolan Capital Management's 13F filing for Q3 2014, filed 13 Nov 2014.